Spyre Therapeutics (SYRE) Current Leases (2019 - 2023)
Spyre Therapeutics' (SYRE) quarterly Current Leases came in at $4.3 million in Q2 2023, up 807.97% YoY from $477000.0 in Q2 2022, and up 612.34% on a QoQ basis from $608000.0 in Q1 2023.
Spyre Therapeutics (SYRE) Current Leases (2019 - 2023) Analysis & Trends
Spyre Therapeutics (SYRE) has 5 years of Current Leases data on file, last reported at $4.3 million in Q2 2023.
- Quarterly Current Leases rose 807.97% year-over-year to $4.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $4.3 million (up 807.97% YoY) and the FY2022 annual result came in at $625000.0, up 43.35% from the prior year.
- Current Leases climbed to $4.3 million in Q2 2023, from $608000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $4.3 million in Q2 2023 to a low of $228000.0 in Q2 2020.
- A 5-year average of $618277.8 and a median of $381500.0 in 2019 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2020 — Current Leases slumped 30.49% — and 2023, when it surged 807.97%.
- Tracing SYRE's Current Leases over 5 years: stood at $351000.0 in 2019, then slipped by 9.12% to $319000.0 in 2020, then soared by 36.68% to $436000.0 in 2021, then jumped by 43.35% to $625000.0 in 2022, then soared by 592.96% to $4.3 million in 2023.
- The last three Current Leases figures came in at $4.3 million (Q2 2023), $608000.0 (Q1 2023), and $625000.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 608,000.00 |
| Dec 31, 2022 | 625,000.00 |
| Sep 30, 2022 | 587,000.00 |
| Jun 30, 2022 | 477,000.00 |
| Mar 31, 2022 | 457,000.00 |
| Dec 31, 2021 | 436,000.00 |
| Sep 30, 2021 | 415,000.00 |
| Jun 30, 2021 | 412,000.00 |
| Mar 31, 2021 | 315,000.00 |
| Dec 31, 2020 | 319,000.00 |
| Sep 30, 2020 | 341,000.00 |
| Jun 30, 2020 | 228,000.00 |
| Mar 31, 2020 | 293,000.00 |
| Dec 31, 2019 | 351,000.00 |
| Sep 30, 2019 | 289,000.00 |
| Jun 30, 2019 | 328,000.00 |
| Mar 31, 2019 | 317,000.00 |